GlassScriptPhysician profile
Larisa Simkhaev
NPI 1215027180
$12,873.74
in general payments reported to CMS, 2019-2025
31 companies · $2,409 in 2025
The $2,409 reported for 2025 was more than what 95% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,553 · 2022: $2,434 · 2023: $2,435 · 2024: $3,043 · 2025: $2,409.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,801 · Education: $85.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,801.12 |
| Education | $85.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,405.11 | 2021-2025 | |
| Pfizer INC. | $1,801.62 | 2023-2025 | |
| Biohaven Pharmaceuticals, INC. | $743.39 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $649.84 | 2021-2025 | Austedo Xr, Austedo, Ajovy |
| Allergan, INC. | $636.91 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $585.05 | 2022 | |
| Eisai INC. | $470.40 | 2023-2025 | |
| Lilly USA, LLC | $467.62 | 2022-2024 | Emgality, Reyvow, Amyvid |
| Merz Pharmaceuticals, LLC | $380.55 | 2024-2025 | Xeomin, Inbrija |
| Lundbeck LLC | $310.78 | 2021-2025 | Vyepti |
| Medtronic, INC. | $298.03 | 2023-2025 | Stealthstation S8 Platform, Percept PC Brainsense, Vanta Adaptivestim |
| Novartis Pharmaceuticals Corporation | $264.28 | 2021 | |
| Amgen INC. | $258.72 | 2021-2024 | Uplizna |
| Axsome Therapeutics, INC. | $222.93 | 2025 | Symbravo |
| Sk Life Science, INC. | $188.71 | 2021-2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scilex Pharmaceuticals INC. | $180.29 | 2022-2025 | Ztlido |
| Neurocrine Biosciences, INC. | $172.65 | 2024 | Ingrezza |
| Abbott Laboratories | $168.81 | 2025 | Infinity |
| Biogen, INC. | $112.49 | 2021-2025 | Leqembi, Skyclarys |
| Neurelis, INC. | $101.78 | 2021-2023 | Valtoco |
| Currax Pharmaceuticals LLC | $101.54 | 2021-2022 | |
| Genzyme Corporation | $93.73 | 2022 | |
| Impel Pharmaceuticals INC. | $84.37 | 2023 | Trudhesa |
| Amylyx Pharmaceuticals, INC. | $33.81 | 2023 | Relyvrio |
| Ge Healthcare | $29.23 | 2025 | |
| Amneal Pharmaceuticals LLC | $25.92 | 2022 | |
| Life Molecular Imaging LTD | $20.46 | 2025 | Neuraceq |
| Vertex Pharmaceuticals Incorporated | $20.30 | 2025 | |
| Janssen Pharmaceuticals, INC | $15.81 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $15.36 | 2024 | |
| Arbor Pharmaceuticals, INC. | $13.25 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Larisa Simkhaev listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.